Abstract:Aims: In silico Identification of Novel SphK1 Inhibitors. Background: A tumor is one of the major causes of death worldwide; the emergence of new targeted drugs has changed the mode of tumor treatment and opened up the era of targeted therapy. Sphingosine kinase 1 (SphK1) is a strictly conserved lipid checkpoint kinase, mainly located in the cytosol, and is overexpressed and enhances the development and progression of various type of tumors, such as melanoma, esophageal, gastric, and colon cancers. SphK1, consisting of 384 amino acid residues, has two domains: C-terminal (CTD) and N-terminal (NTD). SphK1 phosphorylates sphingosine to generate sphingosine-1-phosphate (S1P), which exists in high concentration in both the plasma and the lymph of cancer patients. S1P has 5 receptors (S1PRs) and controls 5 signal pathways, Ras/Raf/MEK1/2, PI3K/Akt, G-protein/PLC/PKC, Rho/Rock/NF-ĸB and PTEN; they are all related to cell growth, proliferation, differentiation, apoptosis, migration, and stress fiber formation. The SphK1/S1P signal pathway influences tumor cells' growth, proliferation, survival and angiogenesis, and SphK1 inhibitors can decrease Treg cell recruitment at tumor location. In T cells, SphK1/S1P signal way activates NF-ĸB and induces proliferator-activated receptor γ (PPARγ) transcription, which in turn regulates lipolysis in T cells. SphK1 can induce T cell failure through excessive S1P in extracellular vesicles of the tumor microenvironment. SphK1 inhibitors block S1P generation and inhibit cell growth, proliferation, differentiation, apoptosis, migration, and stress fiber formation, leading to increased CD8+T cells and decreased Treg cells in the tumor microenvironment. S1P also upregulates the expression of programmed cell death 1 ligand 1(PD-L1) through Early 2-factor transcription factor 1 (E2F1). Objective: The discovery of better Sphk1 inhibitors by pharmacophore model, ADMET, molecular docking, MM/GBSA, and MD simulation. Method: Here, SphK1 pharmacophore was created; first, it was used for virtual screening, ADMET properties of screened-out molecules were predicted, and the obtained molecules were performed molecular docking and Molecular Mechanics Generalized Born Surface Area (MM/GBSA) calculation, then molecular dynamics (MD) simulation was performed, and Molecular Mechanics Poisson-Boltzmann Surface Area (MM/PBSA) were calculated. Result: Compounds 1, 2, and 3 were obtained through screening, and the binding energy of 1, 2, and 3 were better than that of the existing corresponding target inhibitors. Conclusion: The overexpression of SphK1 is closely related to the occurrence, development, migration and drug resistance of tumors and has a good prospect of drug development. Given the important role of SphK1 inhibitors in treating tumors and the shortcomings of clinical application of SphK1 inhibitors, small molecule targeting inhibition SphK1 was screened to overcome the low efficiency. Firstly, estab-lishing a pharmacophore model for virtual screening, and then ADMET prediction, sixty-seven molecules were selected. And then, molecular docking and MM/GBSA calculation obtain three compounds with lower Glide Score. In addition, they both have lower binding energy than PF-543. The docking result shows that Asp167, Asp264, and Thr282 of SphK1 with ligand more easily form H-bonds interaction. Next, in molecular dynamics simulation, compounds 1, 2, and 3 can stably bind with SphK1 and have a high activity of inhibiting SphK1, with more research potential. In conclusion, compounds 1, 2, and 3 inhibit SphK1 laying a foundation for further compound synthesis and activity evaluation. Compounds 1, 2 and 3 can stably bind to the receptor protein, which is valuable for further experimental research.

Unlocking SGK1 inhibitor potential of bis-[1-N,7-N, pyrazolo tetraethoxyphthalimido{-4-(3,5-Dimethyl-4-(spiro-3-methylpyazolo)-1,7-dihydro-1H-dipyrazolo[3,4-b;4',3'-e]pyridin-8-yl)}]p-disubstituted phenyl compounds: a computational study

Identification of Novel Inhibitors Targeting SGK1 via Ensemble-Based Virtual Screening Method, Biological Evaluation and Molecular Dynamics Simulation

Identification, Structure Modification, and Characterization of Potential Small-Molecule SGK3 Inhibitors with Novel Scaffolds

Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

In Silico Identification of Novel SphK1 Inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Molecular Docking, Pharmacophore Modeling, and ADMET Prediction of Novel Heterocyclic Leads as Glucokinase Activators

Molecular Docking, Pharmacophore Mapping, and Virtual Screening of Novel Glucokinase Activators as Antidiabetic Agents

Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors

Design, synthesis, biological evaluation, in silico ADME prediction and molecular docking of pyrazole-benzamides as multitargeting protien kinase inhibitors

Cytotoxic activities of the pyrimidine-based acetamide and isophthalimide derivatives: an in vitro and in silico studies

Discovery of novel pyrrolo[2,3-d]pyrimidine derivatives as anticancer agents: virtual screening and molecular dynamic studies

In Silico Prediction of Inhibitory Effects of Pyrazol-5-one and Indazole Derivatives on GSK3β Kinase Enzyme

Molecular docking, pharmacokinetic prediction and molecular dynamics simulations of tankyrase inhibitor compounds with the protein glucokinase, induced in the development of diabetes

Synthesis of N-(4-chlorophenyl) Substituted Pyrano[2,3-C]pyrazoles Enabling PKBβ/AKT2 Inhibitory and in Vitro Anti-Glioma Activity

Discovery of Small‐Molecules as Potential GSK‐3β Inhibitors for the Treatment of Alzheimer's Disease Using Pharmacophore‐Based Virtual Screening

An In-silico Approach: Design, Homology Modeling, Molecular Docking, MM/GBSA Simulations, and ADMET Screening of Novel 1,3,4-oxadiazoles as PLK1inhibitors

Design, synthesis and biological evaluation of thieno[3,2- c ]pyrazol-urea derivatives as potent glycogen synthase kinase 3β inhibitors based on the DFG-out conformation

Prediction of Protein-Drug Interactions, Pharmacophore Modeling, and Toxicokinetics of Novel Leads for Type 2 Diabetes Treatment

3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents